News Lilly chases Amgen with migraine drug filing Eli Lilly has filed its galcanezumab migraine drug with the FDA, as it looks to claim second place among a group of companies attempting to market a new class of therapies.
News New Teva CEO axes R&D chief Hayden in boardroom shakeup R&D chief Michael Hayden to leave at year end.
News Judge throws out Allergan patents, criticises Native America... Federal court throws out patents on Restasis
News Copaxone first on FDA's list for faster complex generic appr... Teva will attempt to block generic launch in courts
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends